AR/BET protein degrader-1, identified by its CAS number 2571123-81-2, is a small molecule designed to selectively degrade specific proteins involved in various cellular processes. This compound functions through a mechanism known as targeted protein degradation, which utilizes the cellular ubiquitin-proteasome system to tag unwanted proteins for degradation. Characteristically, AR/BET protein degrader-1 exhibits high specificity for its target proteins, which often include transcription factors or other regulatory proteins implicated in diseases such as cancer. The compound is typically characterized by its ability to modulate gene expression and influence cellular pathways by reducing the levels of these target proteins. Additionally, it may possess favorable pharmacokinetic properties, such as good solubility and bioavailability, making it a promising candidate for therapeutic applications. Research into this compound is ongoing, focusing on its efficacy, safety profile, and potential as a treatment strategy in various disease contexts, particularly in oncology.

AR/BET protein degrader-1

2571123-81-2: AR/BET protein degrader-1, identified by its CAS number 2571123-81-2, is a small molecule designed to selectively degrade specific proteins involved in various cellular processes. This compound functions through a mechanism known as targeted protein degradation, which utilizes the cellular ubiquitin-proteasome system to tag unwanted proteins for degradation. Characteristically, AR/BET protein degrader-1 exhibits high specificity for its target proteins, which often include transcription factors or other regulatory proteins implicated in diseases such as cancer. The compound is typically characterized by its ability to modulate gene expression and influence cellular pathways by reducing the levels of these target proteins. Additionally, it may possess favorable pharmacokinetic properties, such as good solubility and bioavailability, making it a promising candidate for therapeutic applications. Research into this compound is ongoing, focusing on its efficacy, safety profile, and potential as a treatment strategy in various disease contexts, particularly in oncology.

AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.

CAS 2571123-81-2

AR/BET protein degrader-1

AR/BET protein degrader-1

Ref: TM-T208967